Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
21-01-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Certificate dated January 2, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.
14-01-2023

AstraZeneca to buy US cardiorenal-drug maker

 Drugs giant will pay $1.3 billion upfront and get the rights to CinCor Pharma's baxdrostat
09-01-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window

 This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Equity Shares of the Company will be closed from December 16, 2022 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending December 31, 2022.
15-12-2022

AstraZeneca Pharma India's MD resigns; appoints Sanjeev Panchal for 3 years

 AstraZeneca Pharma India on Wednesday said Gagandeep Singh Bedi has resigned from the post of managing director. The drug firm said it has approved the appointment of Sanjeev Panchal as its managing director for a period of three years with effect from January 1, 2023. Panchal had joined AstraZeneca Pharma in February 2003 as Brand Associate and progressed through several positions in India, Indonesia, Asia Pacific and the international region, based in Singapore and the United Kingdom (UK), it said.
14-12-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Appointment Of Mr. Sanjeev Panchal (DIN: 09823879) As Additional Director And Also As Managing Director Of The Company

 Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Sanjeev Panchal (DIN: 09823879), as Additional Director and also as Managing Director of the Company for a period of three (3) years with effect from January 1, 2023 subject to the approvals of the Members of the Company through Postal Ballot and Central Government, if so needed. Brief details of Mr. Sanjeev Panchal are enclosed below as 'Annexure- B'.
14-12-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

 This is to inform that the Board of Directors at its Meeting held today i.e., December 14, 2022, considered and transacted inter alia the following business: 1. Noted the Resignation of Mr. Gagandeep Singh Bedi (DIN: 07844333) from the Office of Managing Director and also as Director of the Company with effect from the closing of business hours on December 31, 2022. The details of the resignation are enclosed below as 'Annexure- A'. 2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Sanjeev Panchal (DIN: 09823879), as Additional Director and also as Managing Director of the Company for a period of three (3) years with effect from January 1, 2023 subject to the approvals of the Members of the Company through Postal Ballot and Central Government, if so needed. Brief details of Mr. Sanjeev Panchal are enclosed below as 'Annexure- B'.
14-12-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Certificate dated December 1, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.
05-12-2022

Woman slips into coma after AstraZeneca vaccine dose against Covid-19

 Diagnosed with rare, serious condition
05-12-2022

AstraZeneca India gets regulator's approval to market anti-diabetes drug

 Drug firm AstraZeneca India on Tuesday said it has received approval from the country's drug regulator to market anti-diabetes medication Dapagliflozin. The company said it has received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD). Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said. The approval is applicable for both diabetic and non-diabetic CKD patients, it added. CKD is one of the leading causes of hospitalisation globally and in India, representing a significant clinical and economic burden. "The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country .
29-11-2022
Next Page
Close

Let's Open Free Demat Account